NovoCure

Company Overview

Snapshot

Founded in April 1999 by Prof. Yoram Palti, NovoCure operates with over 1,000 employees. The company has raised a total of $742 million across five funding rounds. In May 2024, NovoCure secured a significant debt financing round, reinforcing its financial position.

Business overview

NovoCure is a commercial-stage oncology company focused on developing Tumor Treating Fields (TTFields) therapy for solid tumor cancers. Its core technology involves low-intensity, intermediate-frequency alternating electric fields that disrupt cell division, leading to cell death. The therapy is delivered via noninvasive, insulated transducer arrays and a portable electric field generator, designed for continuous wear. NovoCure's products, including Optune Lua and Optune Gio, serve the healthcare and life sciences sectors, targeting patients and providers in markets such as the United States, Japan, and Germany.

Strategic signal

In September 2024, NovoCure announced it would present real-world data at ESMO 2024, demonstrating improved survival outcomes for newly diagnosed glioblastoma patients with increased use of Tumor Treating Fields (TTFields) Therapy. This presentation highlights the clinical efficacy and growing adoption of NovoCure's core technology, providing a strong validation of its therapeutic approach and potential for broader market penetration in oncology.

Company Intelligence Q&A

What was a key development for NovoCure in September 2025?

In September 2025, NovoCure obtained approval for its Optune Lua device in Japan for the treatment of unresectable advanced/recurrent non-small cell lung cancer (NSCLC), expanding its market reach and therapeutic indications.

What significant leadership change occurred at NovoCure in September 2024?

In September 2024, NovoCure announced that CEO Asaf Danziger would retire, with CFO Ashley Cordova named as his successor, signaling a transition in the company's executive leadership.

What was the focus of NovoCure's Q3 2024 earnings report?

NovoCure reported its Third Quarter 2024 Financial Results in October 2024, highlighting strong revenue growth amid strategic developments and leadership changes.

What clinical trial collaboration did NovoCure announce in September 2021?

In September 2021, NovoCure announced a clinical trial collaboration with Roche to evaluate Tumor Treating Fields as part of a novel combination for the first-line treatment of metastatic pancreatic cancer.

When did NovoCure go public?

NovoCure went public on NASDAQ in October 2015, raising $165 million in its Initial Public Offering.